Why the study?
Patients with autoimmune-mediated disease may carry an increased risk of DVT and PE, which might increase without immunosuppressive therapy.
Does early anticoagulant therapy reduce mortality from acute pulmonary embolism in patients with myasthenia gravis?
Does early anticoagulant therapy reduce mortality from acute pulmonary embolism in patients with myasthenia gravis?
The authors hypothesize that early anticoagulant therapy may reduce mortality from acute pulmonary embolism in patients with autoimmune-mediated diseases like myasthenia gravis, particularly in the absence of immunosuppressive therapy.
Answers are grounded in this paper and cite their sources.
Early anticoagulation in myasthenia gravis with pulmonary embolism remains unproven; hypothesis-generating case leaves open need for prospective trials.
Patients with an autoimmune-mediated disease may have an increased risk of DVT and PE. We hypothesize that the risk may increase in the absence of immunosuppressive therapy. Hence, anticoagulant therapy may be administered early to reduce mortality from acute PE.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: